Journal articles that question other articles are not peer reviewed like clinical data articles. Comments by credible GBM clinical researchers are credible and read by regulators. Many GBM clinicians work for many of the competitors and does not indicate bias as you claim.
Sorry, the external comparator was not public until the final two weeks of the trial. Peer review is not the same as regulatory approval. FDA has clear guidelines that indicate external comparators MUST be approved PRIOR to the trial beginning, not after the trial is virtually completed.
Novocure trials DID show significantly improved survival benefit -- read the trials.
70 Doctors "behind" the publication were all getting fees from NWBO and were operating trial sites. The publication with the totally new protocol was written by internal NWBO management and their consultants and the 70 clinicians signed on -- they were not independent.
Notice that NWBO didn't file for FDA approval -- because they knew the FDA would reject it. UK approval is never going to provide NWBO with enough revenue to survive. None of the CAR-T immunotherapies have made any material cash after over 5 years of approval.
Market Data 
Markets 
AI
